All Updates

All Updates

icon
Filter
Partnerships
Tavros Therapeutics partners with OpenBench to discover small molecule modulators
Precision Medicine
Apr 27, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Apr 27, 2023

Tavros Therapeutics partners with OpenBench to discover small molecule modulators

Partnerships

  • Drug discovery company Tavros Therapeutics has partnered with screening platform provider OpenBench to identify small molecule modulators for a maximum of five oncology targets within a period of 18 months. The partnership expands their initial collaboration to pursue a first-in-class cancer target. 

  • The collaboration aims to leverage OpenBench's AI chemistry approach and Tavros' synthetic lethality platform to accelerate the discovery of cancer targets. The terms of the agreement include Tavros gaining exclusive access to OpenBench's proprietary screening technology, while OpenBench will receive upfront payment and further compensation upon the successful identification of potent and developable molecules.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.